BCYC Bicycle Therapeutics plc

13.98
+0.33  (+2%)
Previous Close 13.65
Open 13.87
Price To Book 2.7
Market Cap 251,566,913
Shares 17,994,772
Volume 12,643
Short Ratio
Av. Daily Volume 28,418
Stock charts supplied by TradingView

NewsSee all news

  1. Oxurion NV Business Update – FY 2019

    Oxurion NV Business Update – FY 2019   Significant Progress with Innovative Pipeline candidates designed to deliver therapies for Diabetic Eye Disease – Beyond VEGF Positive Results from Phase 1 study evaluating

  2. Bicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates

    - BT1718 on track for Phase IIa initiation in 2020; BT5528 Phase I dose escalation is ongoing; BT8009 on track for Phase I trial initiation in 2020 - IND-enabling activities for lead TICA™ BT7480 continue to

  3. Bicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle®-based Immuno-oncology Therapies

    Bicycle will receive a $30 million upfront payment; upfront payment and potential discovery, development, regulatory and commercial milestones could total up to $1.7 billion Bicycle Therapeutics plc (NASDAQ:BCYC), a

  4. Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME,at Angiogenesis, Exudation, and Degeneration 2020 Conference

    Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME,at Angiogenesis, Exudation, and Degeneration 2020 Conference Phase 2 study with THR-687 in

  5. Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference

    Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 safety and tolerability data released July 1, 2019.
THR-149
Diabetic Macular Edema
Phase 2a trial to commence 2020.
BT1718
Solid tumors
Phase 1 interim data due 2020.
BT5528
Solid tumors
Phase 1 trial to be initiated in 2020.
BT8009
Solid tumors

Latest News

  1. Oxurion NV Business Update – FY 2019

    Oxurion NV Business Update – FY 2019   Significant Progress with Innovative Pipeline candidates designed to deliver therapies for Diabetic Eye Disease – Beyond VEGF Positive Results from Phase 1 study evaluating

  2. Bicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates

    - BT1718 on track for Phase IIa initiation in 2020; BT5528 Phase I dose escalation is ongoing; BT8009 on track for Phase I trial initiation in 2020 - IND-enabling activities for lead TICA™ BT7480 continue to

  3. Bicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle®-based Immuno-oncology Therapies

    Bicycle will receive a $30 million upfront payment; upfront payment and potential discovery, development, regulatory and commercial milestones could total up to $1.7 billion Bicycle Therapeutics plc (NASDAQ:BCYC), a

  4. Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME,at Angiogenesis, Exudation, and Degeneration 2020 Conference

    Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME,at Angiogenesis, Exudation, and Degeneration 2020 Conference Phase 2 study with THR-687 in

  5. Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference

    Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020

  6. Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401

    Cancer Research UK to fund exploratory development of BT7401 through a Phase IIa clinical study Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a

  7. Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME

    Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME                                                         THR-687 is a potent pan-RGD integrin antagonist in

  8. Bicycle Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced

  9. Bicycle Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

    Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced

  10. Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors

    - BT5528 targets EphA2, an antigen believed to be overexpressed in tumor types with high unmet need and a target for which antibody-based approaches have been unsuccessful to date - Phase I dose escalation has

  11. Bicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update

    - BT7480 selected as lead immuno-oncology candidate to advance into IND-enabling studies - Preclinical data on Bicycle® tumor-targeted immune cell agonists to be presented at SITC Annual Meeting on November 9,

  12. Bicycle Therapeutics to Present New Preclinical Data on BT7480, a Novel, Fully Synthetic Bicycle® Tumor-targeted Immune Cell Agonist, at the Society for Immunotherapy of Cancer's 2019 Annual Meeting

    - BT7480 has been selected as the Company's lead immuno-oncology candidate to advance into IND-enabling studies Bicycle Therapeutics plc (NASDAQ:BCYC) a clinical-stage biotechnology company pioneering a new and

  13. Bicycle Therapeutics Announces Appointment of Nigel Crockett, Ph.D., as Chief Business Officer

    Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment

  14. Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford University's Oxford Drug Discovery Institute

    Bicycle to collaborate with ODDI, an organization with deep expertise in the molecular pathology of Alzheimer's disease and CNS drug development Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company

  15. Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress

    - Phase I dose escalation continues; dosing is within the therapeutic range predicted by preclinical models - Early analysis of data shows stable disease in 54% of evaluable patients at eight weeks, across all cohorts

  16. Bicycle Therapeutics to Present Updated Data from Phase I/IIa Trial Evaluating Lead Asset BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress

    Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) product platform, today announced that updated data from the

  17. Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME

           Immediate onset of action - starting from Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149.Prolonged